Systemic glucocorticoids
PreclinicalSmall molecule
Systemic glucocorticoids is one of 28 small molecule programs targeting Chronic Rhinosinusitis. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
27
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
28 competitors in Chronic Rhinosinusitis
#DrugCompanyPhaseTrials
1Pulmicort
SSalix
Approved
Medrol
PfizerApproved
Dupixent
AAzienda U.S.L. 1 di Massa e Carrara
Approved
Rayos
RRoxane Laboratories
Approved
Nucala
GGlaxo Dba Glaxosmithkline
Approved
Zithromax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Asmanex
PPerrigo Company
Approved
Asmanex Hfa
PPerrigo Company
Approved
Prilosec
DDexcel Pharma Technologies Ltd.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Systemic glucocorticoids. EMBL-EBI & Wellcome Sanger Institute.
- [4]